Involvement of reactive oxygen species in multidrug resistance of a vincristine-selected lymphoblastoma.
Our previous study identified a vincristine-selected multidrug resistance (MDR) cell line, HOB1/VCR, derived from a lymphoblastoma HOB1. The HOB1/VCR cells are resistant to typical MDR drugs and are cross-resistant to P-glycoprotein-independent drugs such as cisplatin (cis-diamminedichloroplatinum [II]). The mechanism of this atypical MDR phenotype is uncertain. The present study provides evidence regarding the contribution of reactive oxygen species (ROS) to the resistance of cells in response to treatments (vincristine, cisplatin and H2O2). Notably, the HOB1/VCR cells were cross-resistant to H2O2. High levels of ROS formed in both sensitive and HOB1/VCR cells by H2O2, and moderate levels of ROS were generated by treatment with cisplatin and vincristine. The ROS level in HOB1/VCR cells was lower than that in sensitive cells following treatments. The ROS level was reduced markedly by a non-toxic concentration of N-acetyl-L-cysteine, a ROS scavenger, in drug-treated cells, and was correlated with reduced cytotoxicity. Furthermore, concentrations of glutathione and glutathione peroxidase, but not superoxide dismutase and catalase, increased in HOB/VCR cells. The DL-buthionine-[S,R]-sulfoximine inhibited formation of glutathione and sensitized both cell types to treatments. Therefore, overexpression of an H2O2-reducing system, glutathione-glutathione peroxidase, has a role in resistance. Experimental results further demonstrate that ROS is likely a primary signal in the acquisition of the MDR phenotype and therefore a potential target when designing drugs for chemoresistance.
Tsai
Shih-Ying
SY
Tumor Biology Laboratory, Department of Biochemistry, Chang Gung University, Kwei-Shan Taoyuan 333, Taiwan.
Sun
Nian-Kang
NK
Lu
Hsing-Pang
HP
Cheng
Mei-ling
ML
Chao
Chuck C-K
CC
D017209:Apoptosis; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008223:Lymphoma / Q000378:metabolism*; D017382:Reactive Oxygen Species / Q000378:metabolism*; D014750:Vincristine / Q000494:pharmacology*
D017382:Reactive Oxygen Species; D014750:Vincristine; D002945:Cisplatin